High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients
Table 2
Radiological response to sorafenib in the study.
Item
miR122_H group (n = 294)
miR122_L group (n = 294)
value
12-week radiological response
Complete response (n, %)
4
2
―
Partial response (n, %)
12
3
―
Stable disease (n, %)
67
52
―
Progressive disease (n, %)
211
237
―
Intrahepatic (n, %)
169
184
―
Extrahepatic (n, %)
11
20
―
Both (n, %)
31
33
―
Overall response (n, %)a
16 (5.4)
5 (1.7)
0.015
Disease control (n, %)a
83 (28.2)
57 (19.4)
0.012
24-week radiological response
Complete response (n, %)
1
0
―
Partial response (n, %)
7
1
―
Stable disease (n, %)
19
10
―
Progressive disease (n, %)
267
283
―
Intrahepatic (n, %)
213
225
―
Extrahepatic (n, %)
13
17
―
Both (n, %)
41
41
―
Overall response (n, %)
8 (2.7)
1 (0.3)
0.019
Disease control (n, %)
27 (9.2)
11 (3.7)
0.007
a“Overall response” was the sum of “complete response” + “partial response,” and “disease control” was the sum of “complete response” + “partial response” + “stable disease.”
